Aykut Ferhat Celik

Aykut Ferhat Celik

Auto-generated profile, based on publicly available information

Aykut Ferhat Celik

Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital , Fatih/Istanbul

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2024 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
RMRuth Murphy
Ruth Murphy
RMRobert J Moots
Robert J Moots
PBPaul Brogan
Paul Brogan
AÇAykut F Çelik
Aykut F Çelik
MCMark Clement-Jones
Mark Clement-Jones
ACAlina M Constantin
Alina M Constantin
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of Behçets. The document aims to offer an appraisal of all relevant literature up to 25 August 2023 focusing on any key developments; to address important, practical clinical questions relating to the primary guideline objective; and to provide guideline recommendations and appropriate research recommendations.

6 July 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AHAysa Hacioglu
Aysa Hacioglu
SBSermin Borekci
Sermin Borekci
MMMelike Melikoglu
Melike Melikoglu
YOYesim Ozguler
Yesim Ozguler
SESinem Nihal Esatoglu
Sinem Nihal Esatoglu
GHGulen Hatemi
Gulen Hatemi

28 September 2018 in Turkish Journal of Surgery
Verified
Journal Article
Open access
DADeniz Atasoy
Deniz Atasoy
AAAfag Aghayeva
Afag Aghayeva
EAErman Aytac
Erman Aytac
IEIlknur Erenler
Ilknur Erenler
ACAykut Ferhat Celik
Aykut Ferhat Celik
IHIsmail Hamzaoglu
Ismail Hamzaoglu
Objectives: Crohn's disease is a chronic inflammatory bowel disease that requires lifelong multidisciplinary management. Seventy percent of patients affected by Crohn's disease will require at least one surgical procedure over their lifetime. The aim of this retrospective study was to present our series of patients suffering from Crohn's disease who were scheduled for surgery by a multidisciplinary team. Material and methods: The data were retrieved from a review of 950 patients with Crohn's disease treated at our institution between March 2000 and March 2016. Only patients with intestinal Crohn's disease were included into the study. A multidisciplinary team assessed the decision to perform surgery. Results: There were 203 patients who underwent surgery included in this study. One hundred and sixty-six were intestinal and 37 were perianal Crohn's disease. The mean age was 36 +/- 11.5 (range, 12-75) years. Ninety-two were stricturing, 45 were fistulizing, and 12 were inflammatory. The most commonly affected site was the ileocecal region (n=109, 65.7%), and the most common surgical procedure was the ileocecal resection (n=109, 65.6%). Laparoscopic approach was the procedure of choice in 56 (33.7%) patients. Of the patients enrolled, the most common early (<30 days) complications observed were the wound infection as the first (n=11) and anastomotic leak as the second (n=10). The mortality rate was 2.4% (n=4). Conclusion: Multidisciplinary approach to Crohn's disease may decrease the surgical complications and recurrence rates leading to a better treatment.

15 April 2019 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
MTMurat Toruner
Murat Toruner
HAHale Akpınar
Hale Akpınar
FAFiliz Akyuz
Filiz Akyuz
ÜDÜlkü Dağlı
Ülkü Dağlı
HHHülya Över Hamzaoğlu
Hülya Över Hamzaoğlu
AÇAykut Ferhat Çelik
Aykut Ferhat Çelik
Cite this article as: Törüner M, Akpınar H, Akyüz F, et al. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019; 30(Suppl 4): S913-46.

21 May 2026 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
ABAlessandra Bettiol
Alessandra Bettiol
George BertsiasGeorge Bertsias
George Bertsias
BBBahram Bodaghi
Bahram Bodaghi
ACAykut Ferhat Celik
Aykut Ferhat Celik
GFGeorge E. Fragoulis
George E. Fragoulis
GHGülen Hatemi
Gülen Hatemi

15 May 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
MTMurat Toruner
Murat Toruner
MBMetin Basaranoglu
Metin Basaranoglu
OAOzlen Atug
Ozlen Atug
OSOmer Senturk
Omer Senturk
FAFiliz Akyuz
Filiz Akyuz
TKTaylan Kav
Taylan Kav
Background: Patients with Crohn’s disease experience major deterioration in work productivity and quality of life. We aimed to provide the long-term effects of anti-tumor necrosis factor agents on work productivity and activity impairment and quality of life in patients with Crohn’s disease using the Inflammatory Bowel Disease Questionnaire and the Short-Form Health Survey-36. Methods: Patients with Crohn’s disease and initiated an anti-tumor necrosis factor treatment were included and followed up for 12 months in this observational study. Results: A total of 106 patients were included in this study, and 64.2% of the patients were males. Mean [± standard deviation] age was 36.8 [± 10.9] years. At baseline, mostly perianal fistulas [65.7%] were observed [n = 23]. Intestinal stenosis was detected in 34.9% of the patients [n = 37], and most of the stenosis was located in the ileum [70.6%] followed by the colon [20.6%]. Extraintestinal symp- toms were observed in 24 patients [22.6%]. Most frequent extraintestinal symptom was arthritis with 71.4% [n = 15]. Mean time from first symptom to initiation of anti-tumor necrosis factor treatment was 6.3 [± 5.0] years. Improvements in work productivity and activ- ity impairment scores throughout 12 months were −24.1% [P = .003] for work time missed, −18.0% [P = .006] for impairment at work, −8.5% [P = .160] for overall work impairment, and −17.0% [P < .001] for daily activity impairment. Similarly, significant improvements [P < .001] were detected in all components of the Inflammatory Bowel Disease Questionnaire when compared to baseline. Statistically sig- nificant improvements [P < .05] were detected for all components of Short-Form Health Survey-36 except for mental health [P = .095]. Conclusion: Our study indicates the significant improvement in work productivity and activity impairment and quality of life of patients with Crohn’s disease who receive long-term anti-tumor necrosis factor treatment.